35.81

0.60% 0.215

Travere Therapeutics Inc (TVTX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt TVTX? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$35.60

Offen:

$35.44

24-Stunden-Volumen:

271.31K

Relative Volume:

0.15

Marktkapitalisierung:

$3.20B

Einnahmen:

$333.87M

Nettoeinkommen (Verlust:

$-169.00M

KGV:

-17.56

EPS:

-2.04

Netto-Cashflow:

$-157.30M

1W Leistung:

-9.38%

1M Leistung:

+3.78%

6M Leistung:

+119.32%

1J Leistung:

+88.50%

1-Tages-Spanne:

$35.32

$36.07

1-Wochen-Bereich:

$34.50

$40.75

52-Wochen-Spanne:

$12.91

$42.13

Travere Therapeutics Inc Stock (TVTX) Company Profile

Firmenname

Travere Therapeutics Inc

Sektor

Healthcare (1117)

Branche

Biotechnology (621)

Telefon

888-969-7879

Adresse

3611 VALLEY CENTRE DR, SAN DIEGO

Mitarbeiter

385

Twitter

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

TVTX's Discussions on Twitter

Vergleichen Sie TVTX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TVTX Travere Therapeutics Inc	35.82	3.19B	333.87M	-169.00M	-157.30M	-2.04
VRTX Vertex Pharmaceuticals Inc	472.17	119.17B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	810.41	84.19B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	407.74	52.77B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	811.40	48.98B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.32	36.31B	447.02M	-1.18B	-906.14M	-6.1812

Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-10-31	Bestätigt	Citigroup	Buy
2025-06-11	Bestätigt	Citigroup	Buy
2025-06-11	Fortgesetzt	H.C. Wainwright	Buy
2025-01-10	Eingeleitet	Cantor Fitzgerald	Overweight
2024-10-21	Hochstufung	Wells Fargo	Equal Weight → Overweight
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-09-09	Hochstufung	Guggenheim	Neutral → Buy
2024-03-27	Herabstufung	Guggenheim	Buy → Neutral
2023-12-05	Hochstufung	Citigroup	Neutral → Buy
2023-11-20	Eingeleitet	Citigroup	Neutral
2023-09-22	Herabstufung	Wells Fargo	Overweight → Equal Weight
2023-09-21	Herabstufung	William Blair	Outperform → Mkt Perform
2023-09-06	Fortgesetzt	Evercore ISI	Outperform
2023-07-21	Eingeleitet	JP Morgan	Overweight
2023-06-07	Fortgesetzt	Piper Sandler	Neutral
2023-05-22	Eingeleitet	TD Cowen	Outperform
2023-05-05	Hochstufung	Bryan Garnier	Sell → Neutral
2023-03-01	Eingeleitet	Guggenheim	Buy
2023-02-21	Hochstufung	Wedbush	Neutral → Outperform
2022-12-14	Eingeleitet	Stifel	Hold
2022-12-05	Eingeleitet	Wells Fargo	Overweight
2022-09-21	Eingeleitet	Bryan Garnier	Sell
2022-07-14	Fortgesetzt	Canaccord Genuity	Buy
2022-03-31	Eingeleitet	Piper Sandler	Overweight
2022-02-28	Eingeleitet	H.C. Wainwright	Buy
2021-05-26	Herabstufung	Wedbush	Outperform → Neutral

Alle ansehen

Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten

Jan 08, 2026

How Travere Therapeutics Inc. stock performs in weak economyOil Prices & Real-Time Market Sentiment Reports - ulpravda.ru

Jan 08, 2026

Will Travere Therapeutics Inc. stock maintain momentum in 2025Bear Alert & Verified Chart Pattern Signals - ulpravda.ru

Jan 08, 2026

How Travere Therapeutics Inc. stock reacts to Fed rate cutsJuly 2025 WrapUp & Stepwise Entry/Exit Trade Alerts - ulpravda.ru

Jan 08, 2026

Why Travere Therapeutics Inc. stock could benefit from AI revolutionMarket Trend Summary & Technical Buy Zone Confirmations - ulpravda.ru

Jan 08, 2026

Will Travere Therapeutics Inc. stock remain a Wall Street favorite - ulpravda.ru

Jan 08, 2026

Jan 06, 2026

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears - TechStock²

Jan 06, 2026

How Travere Therapeutics Inc. stock reacts to bond yields2026 world cup usa national team round of 16 goalkeepers possession football tactical prediction breakdown - ulpravda.ru

Jan 06, 2026

Jan 05, 2026

Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 6.1%Time to Sell? - MarketBeat

Jan 05, 2026

Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - MarketScreener

Jan 05, 2026

Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Technical and Fundamental Momentum for Growth Investors - Chartmill

Jan 05, 2026

Jan 03, 2026

Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date - ts2.tech

Jan 03, 2026

Price-Driven Insight from (TVTX) for Rule-Based Strategy - Stock Traders Daily

Jan 03, 2026

Dec 30, 2025

Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 4% Following Insider Selling - MarketBeat

Dec 30, 2025

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shift From Loss To Profit - 富途牛牛

Dec 30, 2025

Travere Therapeutics Insider Sold Shares Worth $2,406,180, According to a Recent SEC Filing - MarketScreener

Dec 30, 2025

Dec 29, 2025

Travere Therapeutics (NASDAQ:TVTX) Insider Peter Heerma Sells 4,980 Shares - MarketBeat

Dec 29, 2025

Inrig Jula, chief medical officer of Travere, sells $630,004 in TVTX - Investing.com Canada

Dec 29, 2025

Travere therapeutics (TVTX) SVP Calvin sells $296k in stock By Investing.com - Investing.com Canada

Dec 29, 2025

Travere therapeutics (TVTX) chief research officer sells $2.4m in stock - Investing.com Canada

Dec 29, 2025

Heerma, Travere therapeutics CCO, sells $199k in TVTX stock By Investing.com - Investing.com Canada

Dec 29, 2025

Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CAO Sells 7,402 Shares of Stock - MarketBeat

Dec 29, 2025

Travere Therapeutics Executives Sell Shares - TradingView — Track All Markets

Dec 29, 2025

Dec 27, 2025

Why Travere Therapeutics stock popped by nearly 14% on Wednesday - MSN

Dec 27, 2025

Dec 26, 2025